Full Press Release Details
Adagene Announces Appointment of Interim Chief
Medical Officer and New Members of Scientific
and Strategic Advisory Board
- Global immuno-oncology experts
bring decades of experience to advance company's
transformative research and development pipeline -
SAN FRANCISCO, Calif. and SUZHOU,
China, August 12, 2021 - Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven,
clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies,
today announced appointment of an interim Chief Medical Officer and new members of its Scientific and Strategic Advisory Board (the "SAB").
The appointments include pioneers in the immuno-oncology field: Steven Fischkoff, M.D., Stanley Frankel, M.D., FACP and Robert Spiegel,
"We are honored to have such a prestigious group with deep therapeutics
development experience to join our efforts in bringing transformative new cancer therapeutics to patients worldwide," said Peter
Luo, Ph.D., Co-Founder, Chief Executive Officer and Chairman of the Board of Adagene. "This team has spearheaded some of the original
immunotherapies, and their strategic vision adds tremendous value to Adagene as we design global development programs to maximize the
potential of our robust pipeline. We are fortunate to work with these talented individuals in leveraging our innovative antibody-based
technology platforms to usher in the next generation of immuno-oncology treatments."
The new appointments include:
Adagene's SAB is comprised of leaders who have played a key
role in the field of immuno-oncology. The SAB will work cohesively with management and other key advisors to provide strategic input
as the company pursues global clinical development of its transformative, expanding pipeline.
For more information about members of the scientific advisory board,
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical
company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational
biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary DPL platform,
composed of NEObody, SAFEbody , and POWERbody technologies, Adagene's highly differentiated pipeline features novel
immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple
approaches at the vanguard of science.
For more information, please visit: https://investor.adagene.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning
of federal securities laws, including statements regarding business plans, which involve risks and uncertainties that could cause the
actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These
statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements
that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements.
Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially
from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases
such as "may", "will," "expect," "anticipate," "target," "aim,"
"estimate," "intend," "plan," "believe," "potential," "continue,"
"is/are likely to" or other similar expressions. Further information regarding these and other risks, uncertainties or factors
is included in the Company's filings with the SEC. All information provided in this press release is as of the date of this press
release, and the Company does not undertake any duty to update such information, except as required under applicable law.